ResMed's Stock Performance: Outperforming Healthcare Peers Amidst Robust Demand and Strong Earnings

ResMed Inc. (RMD) has a market cap of $39.6 billion and operates through Sleep and Breathing Health and Residential Care Software segments. Its stock has surged 18.1% in 2025 and 7.8% over the past 52 weeks, outperforming the Health Care Select Sector SPDR Fund's (XLV) marginal upticks during the same time frames. RMD's performance has remained impressive over the longer term, with the stock trading mostly above its 200-day and 50-day moving averages since late April. The company's Q4 results showed a solid momentum across its business, with net revenues growing 10.2% year-over-year to $1.35 billion.

ResMed Inc. (RMD), a leading provider of medical devices and cloud-based software applications for respiratory disorders, continues to demonstrate strong performance. With a market cap of $39.6 billion, the company operates through the Sleep and Breathing Health and Residential Care Software segments How Is ResMed's Stock Performance Compared to Other Healthcare Stocks?^[1]. The stock has surged 18.1% in 2025 and 7.8% over the past 52 weeks, outperforming the Health Care Select Sector SPDR Fund (XLV) during the same time frames How Is ResMed's Stock Performance Compared to Other Healthcare Stocks?^[1].

RMD's stock has traded mostly above its 200-day and 50-day moving averages since late April, indicating a bullish trend How Is ResMed's Stock Performance Compared to Other Healthcare Stocks?^[1]. The company's Q4 results showed a solid momentum across its business, with net revenues growing 10.2% year-over-year to $1.35 billion, surpassing the Street's expectations by 1.9% How Is ResMed's Stock Performance Compared to Other Healthcare Stocks?^[1]. Non-GAAP EPS soared 22.6% year-over-year to $2.55, exceeding the consensus estimates by 3.7% How Is ResMed's Stock Performance Compared to Other Healthcare Stocks?^[1].

Institutional investors and hedge funds own 54.98% of the company's stock, with significant holdings from Zurich Insurance Group Ltd FI, MBB Public Markets I LLC, United Services Automobile Association, Great Lakes Advisors LLC, Goldman Sachs Group Inc., and Jones Financial Companies Lllp ResMed Inc. $RMD Shares Sold by Zurich Insurance Group Ltd FI^[2]. The company has also seen insider selling, with directors John Hernandez and Peter C. Farrell selling shares in recent transactions ResMed Inc. $RMD Shares Sold by Zurich Insurance Group Ltd FI^[2].

ResMed Inc. recently announced a quarterly dividend of $0.60 per share, representing a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, August 14th ResMed Inc. $RMD Shares Sold by Zurich Insurance Group Ltd FI^[2]. The company's dividend payout ratio is currently 25.24% ResMed Inc. $RMD Shares Sold by Zurich Insurance Group Ltd FI^[2].

Analysts have issued various ratings and price targets for RMD. William Blair raised ResMed to a "strong-buy" rating, while Piper Sandler boosted their price target to $270.00 with a "neutral" rating ResMed Inc. $RMD Shares Sold by Zurich Insurance Group Ltd FI^[2]. CLSA raised ResMed to an "outperform" rating, and Stifel Nicolaus boosted their price target to $270.00 with a "hold" rating ResMed Inc. $RMD Shares Sold by Zurich Insurance Group Ltd FI^[2]. Wall Street Zen downgraded ResMed from a "buy" rating to a "hold" rating ResMed Inc. $RMD Shares Sold by Zurich Insurance Group Ltd FI^[2]. The consensus rating among analysts is "Moderate Buy" with an average price target of $278.36 ResMed Inc. $RMD Shares Sold by Zurich Insurance Group Ltd FI^[2].

ResMed Inc. continues to show robust growth and strong fundamentals, positioning itself as a key player in the healthcare sector.